# A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

Study · id `cardio:ct-nct06362759` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06362759](<https://clinicaltrials.gov/study/NCT06362759>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06362759

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 143 participants.

## Technical summary

Registry record NCT06362759. Randomized; quadruple masking; primary purpose treatment. Start 2024-05-15 (actual); primary completion 2025-03-06 (actual). Results posted on 2026-08-11.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 143 participants (enrolled count; ClinicalTrials.gov record NCT06362759, source copy `cardio:ctgov-nct06362759-2026-08-11`, retrieved 2026-10-26)
- Started: 2024-05-15 (actual) (ClinicalTrials.gov record NCT06362759, source copy `cardio:ctgov-nct06362759-2026-08-11`, retrieved 2026-10-26)
- Primary completion: 2025-03-06 (actual) (ClinicalTrials.gov record NCT06362759, source copy `cardio:ctgov-nct06362759-2026-08-11`, retrieved 2026-10-26)
- Completion: 2025-12-04 (actual) (ClinicalTrials.gov record NCT06362759, source copy `cardio:ctgov-nct06362759-2026-08-11`, retrieved 2026-10-26)
- Results first posted: 2026-08-11 (ClinicalTrials.gov record NCT06362759, source copy `cardio:ctgov-nct06362759-2026-08-11`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06362759, source copy `cardio:ctgov-nct06362759-2026-08-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06362759-2026-08-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP
- Acronym: TRANQUILITY
- Condition: Chronic Kidney Diseases
- Condition: Chronic Kidney Insufficiency
- Condition: Chronic Renal Diseases
- Condition: Chronic Renal Insufficiency
- Condition: Kidney Insufficiency, Chronic
- Condition: C-Reactive Protein
- Condition: High Sensitivity C-Reactive Protein
- Condition: Hs-CRP
- Condition: hsCRP
- Intervention (Drug): TOUR006 - 50 MG
- Intervention (Drug): TOUR006 - 25 MG
- Intervention (Drug): TOUR006 - 15 MG
- Intervention (Other): Placebo
- Lead sponsor: Tourmaline Bio, Inc., a Novartis Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: a66cc1cfe1f2b1e85b23ade5bf0c449348f0e4da30727c74aa45a0b35d5c6c3c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
